Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Mount Everest Climbers 'Poisoned' by Guides Prompting Mass Helicopter Rescues in $20 Million Insurance Fraud Scheme, Police Say- Israel has clear objectives south of Litani River, but will face difficult choices further north
- Flights canceled at 40 U.S. airports: Follow live updates as FAA cuts to air traffic take effect amid government shutdown
- Most loved Caf\u00e9 Chain: Where Do You Get Your Caffeine Fix
- Exhaustive Experiences into Prudent Senior Living in the UK
- Ancient fire discovery marks significant milestone in human history
- Figure out how to Consolidate a Brain science Certificate with Social Work
- Figure out How to Augment Eco-friendliness in Your Volvo XC40
- Everyday Seasonal Positions That Compensate Fairly in the US
